Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 23;52(1):e7952.
doi: 10.1590/1414-431X20187952.

NOP14 inhibits melanoma proliferation and metastasis by regulating Wnt/β-catenin signaling pathway

Affiliations

NOP14 inhibits melanoma proliferation and metastasis by regulating Wnt/β-catenin signaling pathway

Jingrong Li et al. Braz J Med Biol Res. .

Erratum in

Abstract

Malignant melanoma is an aggressive skin cancer with a high mortality rate. Nucleolar protein 14 (NOP14) has been implicated in cancer development. However, the role of NOP14 in malignant melanoma progression remains largely unclear. In this study, we observed that malignant melanoma tissue showed NOP14 down-regulation compared to melanocytic nevi tissues. Moreover, we observed that NOP14 expression was significantly associated with melanoma tumor thickness and lymph node metastasis. NOP14 overexpression in melanoma cells suppressed proliferation, caused G1 phase arrest, promoted apoptosis, and inhibited melanoma cell migration and invasion. Further investigations revealed that NOP14 overexpression reduced the expression levels of Wnt3a, β-catenin, and GSK-3β of the Wnt/β-catenin pathway. In summary, we demonstrated that NOP14 inhibited melanoma cell proliferation and metastasis by regulating the Wnt/β-catenin signaling pathway.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Expression level of nucleolar protein 14 (NOP14) in malignant melanoma tissues and melanocytic nevi tissues. Scale bar: 50 μm.
Figure 2.
Figure 2.. Effect of nucleolar protein 14 (NOP14) overexpression on melanoma cell proliferation. NOP14 mRNA levels (A) and protein levels (B) in melanoma cell lines transfected with NOP14 overexpression and empty vectors. C and D, Cell proliferation analysis of melanoma cells after transfection of NOP14 overexpression and empty vectors. Data are reported as means±SD. **P<0.01 vs empty vector (ANOVA).
Figure 3.
Figure 3.. Apoptosis and cell cycle analysis of melanoma cells transfected with nucleolar protein 14 (NOP14) overexpression or empty vector. A and B, Apoptosis analysis of melanoma cells. C and D, Cell cycle analysis of melanoma cells. Data are reported as means±SD. **P<0.01 vs empty vector (t-test).
Figure 4.
Figure 4.. Migratory ability and invasiveness of melanoma cells determined by transwell assay. NOP14: nucleolar protein 14. Scale bar: 50 μm. Data are reported as means±SD. **P<0.01 vs empty vector (t-test).
Figure 5.
Figure 5.. Expression level of Wnt3a, β-catenin, and GSK-3β in melanoma cells. A to C, Relative expression and D, protein levels of Wnt3a, β-catenin, and GSK-3β in melanoma cells transfected with nucleolar protein 14 (NOP14) overexpression and empty vectors. Data are reported as means±SD. *P<0.05, **P<0.01 vs empty vector (ANOVA).

Similar articles

Cited by

References

    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. - DOI - PubMed
    1. Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol. 2013;6:18–26. - PMC - PubMed
    1. Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int J Cancer. 2013;132:385–400. doi: 10.1002/ijc.27616. - DOI - PubMed
    1. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007;109:455–464. doi: 10.1002/cncr.22427. - DOI - PubMed
    1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516. doi: 10.1056/NEJMoa1103782. - DOI - PMC - PubMed

MeSH terms